Stage (next event)
Phase 3 Initiation
Catalyst Info & Data Links
TITLE: CTP-543 for Alopecia Areata - Phase 3
ClinicalTrial.gov (NCT04518995): A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-05-2020 2020 Third Quarter Financial Results
Mechanism of Action
MECHANISM OF ACTION
CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.
Updated by JM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post